RT Journal Article
SR Electronic
T1 Targeting Protein Serine/Threonine Phosphatases for Drug Development
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 1249
OP 1261
DO 10.1124/mol.108.053140
VO 75
IS 6
A1 Jamie L. McConnell
A1 Brian E. Wadzinski
YR 2009
UL http://molpharm.aspetjournals.org/content/75/6/1249.abstract
AB With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity. The American Society for Pharmacology and Experimental Therapeutics